PainReform Ltd.

2.05
0.06 (3.02%)
At close: Apr 17, 2025, 3:59 PM
2.00
-2.39%
After-hours: Apr 17, 2025, 07:52 PM EDT

Company Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel.

It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair.

PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

PainReform Ltd.
PainReform Ltd. logo
Country IL
IPO Date Sep 1, 2020
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 2
CEO Dr. Ehud Geller Ph.D.

Contact Details

Address:
65 Yigal Alon Street
Tel Aviv,
IL
Website https://www.painreform.com

Stock Details

Ticker Symbol PRFX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001801834
CUSIP Number M77798102
ISIN Number IL0011651580
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Ehud Geller Ph.D. Interim Chief Executive Officer & Executive Chairman
Dr. Sigal Aviel eMBA, Ph.D. Chief Operating Officer
Eyal Broder Interim Chief Financial Officer
Prof. Eli Hazum Ph.D. Chief Technology Officer & Director
Dr. Stephen A. Cooper D.M.D Ph.D. Executive Vice President of Development
Rita Keynan Vice President of Pharmaceutical Operations

Latest SEC Filings

Date Type Title
Apr 17, 2025 6-K Filing
Apr 11, 2025 6-K Filing
Apr 10, 2025 6-K Filing
Apr 07, 2025 6-K Filing
Apr 07, 2025 20-F Filing
Apr 03, 2025 6-K Filing
Mar 05, 2025 6-K Filing
Feb 27, 2025 6-K Filing
Feb 26, 2025 6-K Filing
Feb 18, 2025 6-K Filing